MétaCan
Menu
Back to cohort
Record W2914527787 · doi:10.1016/j.jaip.2019.01.021

Fixed-Dose Subcutaneous C1-Inhibitor Liquid for Prophylactic Treatment of C1-INH-HAE: SAHARA Randomized Study

2019· article· en· W2914527787 on OpenAlexafffund
William R. Lumry, Inmaculada Martinez‐Saguer, William H. Yang, Jonathan A. Bernstein, Joshua Jacobs, Dumitru Moldovan, Marc A. Riedl, Douglas Johnston, H. Henry Li, Yongqiang Tang, Jennifer Schranz, Peng Lü, Moshe Y. Vardi, Henriette Farkas, Paul K. Keith, W.H. Yang, Marcus Maurer, Avner Reshef, Shmuel Kivity, Teresa Caballero, Mar Guilarte, Teresa Gonzalez‐Quevedo, Aleena Banerji, Againdra K. Bewtra, Timothy Craig, Stanley M. Fìneman, Richard Gower, Jay M. Kashkin, H.H. Li, Michael R. Manning, Donald McNeil, Isaac Melamed, Nayla Mumneh, T. Nickel, J. Panuto, Daniel Soteres, Raffi Tachdjian, J. Offenberger, James H. Wedner

Bibliographic record

VenueThe Journal of Allergy and Clinical Immunology In Practice · 2019
Typearticle
Languageen
FieldMedicine
TopicCoagulation, Bradykinin, Polyphosphates, and Angioedema
Canadian institutionsOttawa Allergy Research CorporationUniversity of Ottawa
FundersSwedish Orphan BiovitrumBioCrystGenentechValeant Pharmaceuticals InternationalRegeneron PharmaceuticalsAlnylam PharmaceuticalsNorth Carolina GlaxoSmithKline Foundation3MRocheSanofiMerckGlaxoSmithKlineGaldermaAimmune TherapeuticsCSL BehringShireAstraZenecaTeva Pharmaceutical IndustriesNovartisPfizer
KeywordsMedicineC1-inhibitorProphylactic treatmentRandomized controlled trialSurgeryInternal medicineAngioedema

Abstract

fetched live from OpenAlex

BACKGROUND: Hereditary angioedema (HAE) with C1 inhibitor deficiency (C1-INH) is characterized by swelling of subcutaneous and/or submucosal tissues. OBJECTIVE: To evaluate efficacy/safety of fixed-dose subcutaneous plasma-derived C1-INH (pdC1-INH) liquid for HAE attack prevention (NCT02584959). METHODS: Eligible patients were ≥12 years with ≥2 monthly attacks prescreening or pre-long-term prophylaxis. In a partial crossover design, 80% of patients were randomized to placebo or pdC1-INH liquid for 14 weeks and crossed over from active to placebo or vice versa for another 14 weeks. The remainder were randomized to pdC1-INH liquid for 28 weeks. The primary efficacy endpoint was normalized number of attacks (NNA) versus placebo. Key additional endpoints were the proportion of patients achieving NNA reduction ≥50%, attack severity, number of attack-free days, and safety. RESULTS: Seventy-five patients were randomized and 58 (77%) completed the study. Mean age 41 years; 88% HAE type I. Least-squares means of NNA were reduced from 3.9 with placebo to 1.6 with pdC1-INH (from day 1; P < .0001). Most patients had ≥50% NNA reduction with pdC1-INH (from day 1, 78%). A total of 8.8% of placebo-treated patients were attack-free and 5.3%, 22.8%, and 63.2% had mild, moderate, and severe attacks, respectively; 37.5% of pdC1-INH-treated patients were attack-free and 8.9%, 26.8%, and 26.8% had mild, moderate, and severe attacks, respectively. Treatment-emergent adverse event rates were similar between groups (52% vs 56% for pdC1-INH crossover vs placebo, respectively). CONCLUSIONS: Fixed-dose subcutaneous pdC1-INH liquid was superior to placebo in preventing HAE attacks and demonstrated a favorable safety profile.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.003
metaresearch head score (Gemma)0.003
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Randomized trial · Consensus signal: Randomized trial
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.012
Threshold uncertainty score0.040

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0030.003
Meta-epidemiology (narrow)0.0010.001
Meta-epidemiology (broad)0.0040.002
Bibliometrics0.0010.001
Science and technology studies0.0010.001
Scholarly communication0.0010.001
Open science0.0010.001
Research integrity0.0020.002
Insufficient payload (model declined to judge)0.0120.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.024
GPT teacher head0.356
Teacher spread0.332 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designRandomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations16
Published2019
Admission routes2
Has abstractyes

Explore more

Same venueThe Journal of Allergy and Clinical Immunology In PracticeSame topicCoagulation, Bradykinin, Polyphosphates, and AngioedemaFrench-language works237,207